ATTR amyloidosis is a progressive, often fatal disease in which the protein transthyretin, normally a stable workhorse that ferries thyroid hormone and vitamin A through the bloodstream, falls apart and clumps into stiff fibers called amyloid that accumulate in the heart, nerves, and other organs. It comes in two forms: a hereditary version driven by gene mutations, and a “wild-type” version with no mutation at all, linked mainly to aging. For decades it was considered rare and untreatable, but a surge in diagnostic capability and several new therapies have dramatically changed the landscape. The disease is still underdiagnosed, but for many patients it is no longer a death sentence.
What Transthyretin Does When It Works Properly
Transthyretin (TTR) is a protein produced mainly by the liver and, to a lesser extent, by the choroid plexus in the brain. Under normal conditions it forms a compact four-part structure, a tetramer, that carries thyroxine (a thyroid hormone) and retinol-binding protein (which delivers vitamin A) through the blood and cerebrospinal fluid.1PubMed Central. The role of transthyretin in cell biology: impact on human pathophysiology The tetramer is sturdy in healthy people, circulating without incident for a normal lifespan. The trouble starts when the tetramer falls apart.
How the Protein Goes Wrong
The core problem in ATTR amyloidosis is destabilization of that tetramer. When it splits into individual subunits (monomers), those monomers can misfold into shapes that stick together, forming long, insoluble fibrils that deposit in tissues.2PubMed Central. A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis) In the hereditary form (ATTRv, where “v” stands for variant), specific gene mutations make the tetramer inherently less stable. Research on the structure of amyloid fibrils from patients with different mutations has shown that the mutations’ primary role is promoting the unfolding and dissociation of the native tetramer, pushing the protein into highly aggregation-prone states.3Nature Communications. Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis In the wild-type form (ATTRwt), the protein has no mutation but still destabilizes over time, which is why ATTRwt overwhelmingly affects older adults.
Two Forms of the Same Disease
The hereditary form, ATTRv, is caused by any of over 130 known mutations in the TTR gene. In the United States, the most common mutation is Val122Ile, which is carried by roughly 3 to 4 percent of African Americans. A large registry found that Val122Ile accounted for about 45% of hereditary cases in the U.S., followed by Thr60Ala at about 20%.4PubMed Central. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey) Val30Met is the most common mutation globally, especially in endemic areas like Portugal, Sweden, and Japan.
The wild-type form, ATTRwt, has no genetic mutation and was historically called “senile cardiac amyloidosis.” It primarily affects men over 70 and is increasingly recognized as a significant cause of heart failure with preserved ejection fraction in older adults. A comparison of the two forms in patients over 70 showed that those with wild-type disease were slightly older at diagnosis (about 80 versus 77 years) and overwhelmingly male (over 90%), while hereditary patients were more frequently female, more often of Afro-Caribbean ethnicity, and had higher rates of nerve involvement.5European Journal of Heart Failure. Prevalence, Characteristics and Outcomes of Older Patients with Hereditary Versus Wild-Type Transthyretin Amyloid Cardiomyopathy
What Different Mutations Do to the Body
Not all mutations behave alike. A study comparing three common hereditary variants illustrated how dramatically the clinical picture can shift depending on the mutation involved. Patients with the Val122Ile mutation had the worst cardiac burden, with the highest levels of a heart-failure biomarker called proBNP and the thickest heart walls, but relatively mild nerve damage. By contrast, patients with the Val30Met and Leu58His mutations had more severe nerve impairment and more gastrointestinal symptoms, while their hearts were less affected. Carpal tunnel syndrome was extremely common across all three groups.6PubMed Central. Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis This variation partly explains why the disease is so often missed: a cardiologist may not think to test for amyloidosis in a patient whose nerve symptoms dominate, and a neurologist may overlook it in someone whose main problem is heart failure.
The Heart Takes the Biggest Hit
Cardiac involvement is the leading cause of death in ATTR amyloidosis. Amyloid fibrils infiltrate the heart muscle, causing the walls to thicken and stiffen. The result is diastolic dysfunction, meaning the heart can fill with blood during rest phases but does so poorly, gradually progressing toward a restrictive pattern where the heart becomes so stiff it can barely expand at all.7PubMed Central. Cardiac amyloidosis: the need for early diagnosis Patients develop exercise intolerance, shortness of breath, and fluid retention. Atrial fibrillation is common, especially in wild-type disease, where nearly 60% of patients have it at diagnosis.8European Journal of Heart Failure. Prevalence, Characteristics and Outcomes of Older Patients with Hereditary Versus Wild-Type Transthyretin Amyloid Cardiomyopathy
One reason cardiac ATTR amyloidosis went unrecognized for so long is that it can look like garden-variety heart failure with a thick heart on an echocardiogram. Older men with stiff, thick-walled hearts were often assumed to have hypertensive heart disease. The shift in awareness has been significant: autopsy studies have suggested that a meaningful fraction of older adults with heart failure actually had undiagnosed ATTR amyloidosis.
Nerve Damage and Autonomic Dysfunction
In the hereditary form especially, amyloid deposits in the peripheral nerves lead to a rapidly progressive sensory-motor neuropathy. The fibrils initially accumulate in the nerve root ganglia, causing damage that works its way outward over time. As the disease advances, patients lose sensation starting in the feet, then develop weakness that can become severe.9PubMed Central. The neuropathy in hereditary transthyretin amyloidosis: A narrative review In a UK cohort, the neuropathy was characterized as predominantly length-dependent and axonal, though patients with the Thr60Ala mutation had an earlier and more distinctive pattern that included significant vibration loss and a motor deficit that didn’t strictly follow the usual bottom-up progression.10Journal of Neurology, Neurosurgery & Psychiatry. A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK
Autonomic dysfunction, where the nerves controlling involuntary body functions are damaged, is another hallmark. This can cause orthostatic hypotension (dizziness when standing), erectile dysfunction, bladder problems, and gastrointestinal disturbances. In one study of hereditary ATTR patients, autonomic dysfunction affected about 73% of the cohort.11Scientific Reports. Polyneuropathy in hereditary and wildtype transthyretin amyloidosis, comparison of key clinical features and red flags Wild-type patients can also develop neuropathy, though it tends to be milder and overshadowed by cardiac symptoms.
Gastrointestinal Symptoms and Weight Loss
Gut involvement is common enough that it deserves separate attention, yet it is often one of the last things clinicians associate with ATTR amyloidosis. In a large international registry, about 63% of patients with hereditary ATTR and 15% of those with wild-type disease reported gastrointestinal symptoms. Unintentional weight loss was the most frequent complaint, reported by roughly a third of hereditary patients, followed by early satiety. Patients with early-onset disease (before age 50) and those with the Val30Met mutation had the highest rates. Both upper and lower gut symptoms were associated with worse nutritional status and quality of life.12BioMed Central. THAOS: gastrointestinal manifestations of transthyretin amyloidosis – common complications of a rare disease Diarrhea, constipation, and nausea can alternate unpredictably, and unexplained weight loss in someone with neuropathy or heart failure should raise a flag.
Carpal Tunnel and Spinal Stenosis as Early Clues
One of the most actionable findings in recent years is that carpal tunnel syndrome (CTS) and lumbar spinal stenosis (LSS) often appear years before ATTR amyloidosis is diagnosed. Amyloid deposits thicken the ligaments in the wrist and spine well before the heart or peripheral nerves show obvious damage. A large study found that patients with CTS had roughly triple the likelihood of a later amyloidosis diagnosis compared to matched controls, while those with spinal stenosis had about double the risk. When both conditions were present, the 10-year rate of amyloidosis diagnosis rose to about 1.45%.13PubMed Central. Spinal Stenosis and Carpal Tunnel Syndrome as Surrogates of Transthyretin Amyloid Cardiomyopathy
The latency between carpal tunnel surgery and eventual amyloidosis diagnosis can be long, sometimes a decade or more.14PubMed. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy? This means the opportunity for early detection is substantial. Some clinicians are now advocating that tissue removed during carpal tunnel release surgery be routinely tested for amyloid, especially in older men or anyone with known risk factors.
How ATTR Amyloidosis Is Diagnosed
For suspected cardiac involvement, the diagnostic landscape has been transformed by a nuclear medicine scan using technetium-99m pyrophosphate (in the U.S.) or similar bone-seeking tracers. These tracers have a strong affinity for ATTR amyloid in the heart and can confirm the diagnosis without a biopsy in many cases. One study found that planar imaging at just one hour had 98% sensitivity and 96% specificity for ATTR cardiac amyloidosis, and that no patient with the other major type of cardiac amyloidosis (AL, caused by light-chain proteins) had a positive result on the more detailed SPECT portion of the scan.15PubMed Central. Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis This distinction matters enormously because AL amyloidosis requires chemotherapy-based treatment, while ATTR amyloidosis does not.
Before relying on the bone scan alone, clinicians must rule out AL amyloidosis with blood and urine tests for abnormal light chains. If those tests are negative and the scan is strongly positive, the diagnosis of ATTR cardiac amyloidosis can be made without an endomyocardial biopsy, which was previously the gold standard.16PubMed Central. The use of PYP scan for evaluation of ATTR cardiac amyloidosis at a tertiary medical centre Cardiac MRI can also help distinguish ATTR from AL amyloidosis. A scoring system based on late gadolinium enhancement patterns detected ATTR amyloidosis with 87% sensitivity and 96% specificity when combined with age and wall thickness data.17PubMed. CMR-based differentiation of AL and ATTR cardiac amyloidosis
Genetic testing is essential after any ATTR diagnosis is confirmed, because distinguishing hereditary from wild-type disease changes treatment options, family screening needs, and prognosis.
Tracking Disease Progression
Once diagnosed, monitoring involves a combination of blood tests, imaging, and functional assessments. Standard cardiac biomarkers, particularly troponin and NT-proBNP (a marker of heart wall stress), can signal worsening amyloid deposition even before symptoms change.18PubMed Central. Biomarkers in Subclinical Transthyretin Cardiac Amyloidosis The six-minute walk test, a simple measure of how far someone can walk in six minutes, is widely used to track functional decline. Clinicians also follow kidney function, diuretic requirements, and structural changes on cardiac imaging.19PubMed. How to monitor disease progression in ATTR amyloid cardiomyopathy: Implications for clinical practice and trial design For patients with nerve involvement, neurofilament light chain, a protein released when nerve fibers are damaged, is being explored as a way to catch neuropathy progression early.
Tafamidis and TTR Stabilization
The first major treatment breakthrough was tafamidis, a small molecule that wedges itself into the thyroxine-binding sites of the TTR tetramer and prevents it from falling apart. In the landmark ATTR-ACT trial, tafamidis reduced all-cause mortality compared to placebo (about 30% versus 43% over 30 months), lowered cardiovascular hospitalizations by roughly a third, and slowed the decline in both walking capacity and quality of life.20PubMed. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy The drug was well tolerated, with side effects no different from placebo.21PubMed. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy
Tafamidis has effectively replaced liver transplantation as the first-line therapy for hereditary ATTR amyloidosis.22PubMed. Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis Transplantation was once the only option because the liver produces most of the body’s TTR; replacing it with a donor liver that makes normal protein stops the production of mutant TTR. But transplant carries surgical risk, requires lifelong immunosuppression, and does not address wild-type TTR production by the new liver or localized TTR production in the eyes and brain. Tafamidis avoids all of those issues, though it stabilizes the protein rather than eliminating it, meaning amyloid that has already been deposited stays in place.
Gene Silencing Approaches
A different strategy attacks the problem upstream by reducing how much TTR the liver makes in the first place. Two classes of drugs do this: small interfering RNA (siRNA) drugs and antisense oligonucleotides (ASOs).
Patisiran, an siRNA drug, was the first gene-silencing therapy approved for hereditary ATTR polyneuropathy. Vutrisiran, a newer siRNA given as a subcutaneous injection every three months rather than an intravenous infusion every three weeks, followed. Both work by intercepting the messenger RNA that encodes TTR before it can be translated into protein.
On the antisense side, inotersen was the first ASO approved for hereditary ATTR polyneuropathy. It blocks TTR production in the liver but requires monitoring for rare but serious side effects, including low platelet counts and kidney inflammation.23PubMed Central. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis Eplontersen, a next-generation ASO, improves on inotersen by using a liver-targeting molecule attached to the drug, allowing lower doses and better tolerability. In its pivotal trial, eplontersen significantly lowered serum TTR concentrations and improved nerve impairment and quality of life, with a safety profile not significantly different from the control group.24PubMed Central. A review of Eplontersen use in hereditary transthyretin amyloidosis
These gene-silencing drugs reduce circulating TTR by 80% or more, which means less raw material available to misfold. They do not, however, clear amyloid already deposited in tissues.
CRISPR Gene Editing
Perhaps the most striking development is the application of CRISPR-Cas9 gene editing directly inside patients’ bodies. An investigational therapy called nexiguran ziclumeran (nex-z, formerly known as NTLA-2001) uses lipid nanoparticles to deliver CRISPR components to the liver, where they permanently knock out the TTR gene. In early-phase clinical data, a single intravenous infusion reduced serum TTR levels by about 87% at the higher dose within 28 days, with reductions persisting through follow-up.25PubMed. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis In a subsequent cohort that included patients with more advanced heart failure, mean TTR reductions exceeded 90% and held steady through four to six months.26PubMed Central. Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy
A phase 1 study reported that the TTR reduction from a single dose of nex-z was about 89% at 28 days and held at about 90% at 12 months, with the main side effects being transient infusion-related reactions.27PubMed. CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy If larger trials confirm durable efficacy and safety, gene editing could eventually offer a one-time treatment that replaces the need for ongoing drug infusions or injections. That said, permanently eliminating a protein that normally carries thyroid hormone and vitamin A raises questions about long-term consequences that only longer follow-up will answer.
Removing Amyloid That Has Already Been Deposited
All the therapies above address the supply side: they either stabilize the protein or shut down its production. None of them clear the amyloid fibrils already sitting in the heart or nerves. This is a critical gap, because many patients are diagnosed with a substantial amyloid burden. Researchers have developed an antibody called NI301A, a fully human immunoglobulin that selectively binds to misfolded ATTR aggregates without touching the normal circulating protein. In preclinical work, NI301A removed ATTR deposits from patient-derived heart tissue using macrophages, essentially enlisting the immune system to eat the amyloid away.28Nature Communications. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells Clinical trials of this and similar antibodies are underway. If an amyloid-clearing drug can be combined with a TTR-lowering drug, the logic would be to simultaneously stop new amyloid from forming and remove what has already accumulated, which could be transformative for patients diagnosed at later stages.
The Financial Reality
Even with effective treatments now available, access is a real concern. Tafamidis carries a list price that runs into six figures per year in the United States, and the newer gene-silencing drugs are similarly expensive. A survey of over 450 patients with ATTR amyloidosis found that 55% reported financial toxicity from their care. Many delayed treatment or dipped into savings and borrowed money to cover costs. The financial distress was comparable to what cancer patients experience.29PubMed. Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey Insurance coverage varies, prior authorizations can be burdensome, and patients who fall into coverage gaps face impossible choices. For a disease where early treatment matters most, financial barriers that delay therapy effectively rob patients of the window when drugs work best.
Why Early Diagnosis Changes Everything
The single most important practical message for anyone reading about ATTR amyloidosis is that catching it early makes a measurable difference. The tafamidis trial showed that patients with less advanced heart failure benefited more than those enrolled at later stages. Gene-silencing drugs work by stopping new amyloid production, so logically they are more useful when the existing amyloid burden is smaller. And once the heart has been severely infiltrated, the damage is difficult to reverse with any current therapy.
The challenge is that early ATTR amyloidosis can look like many other things: unexplained heart failure with a thick heart wall, idiopathic neuropathy, bilateral carpal tunnel syndrome that recurs after surgery, chronic gastrointestinal complaints with unexplained weight loss. Awareness among non-specialist physicians is growing but remains insufficient. If you have a combination of these symptoms, especially with a family history of amyloidosis, heart failure, or early death from cardiac causes, asking a doctor specifically about amyloidosis testing is reasonable. For older men with heart failure and a thick-walled heart on echocardiography, a bone-tracer scan should be part of the standard workup. The test is widely available, noninvasive, and can spare years of misdiagnosis.